Tesamorelin
GHRH analog for lipodystrophy and body composition research.
Add 2 more to unlock 17% off
Questions? Reach us directly. Message on WhatsApp (Business Mobile — avg 1-hr response) or email admin@dmvresearch.shop.
For in-vitro and pre-clinical research use only. Not for human consumption, therapeutic use, or veterinary application. Research Use Only Policy
Free shipping
On orders over $150
Damage protection
Replacement on broken vials
Secure checkout
256-bit SSL
Compound Information
Updated 2026-06-08Technical specifications
A synthetic analog of growth-hormone-releasing hormone (GHRH) with a stabilizing trans-3-hexenoyl modification at the N-terminus. Studied at the GHRH receptor in somatotropic-axis research models.
What Is Tesamorelin?
- Type
- Synthetic Peptide (GHRH Analog)
- Molecular Weight
- 5,136 g/mol
- Molecular Formula
- C₂₂₁H₃₆₆N₇₂O₆₇S
- Amino Acids
- 44
- Primary Target
- GHRH receptor (GHRHR)
Stability Information
Lyophilized (powder)
-20°C· stable
Reconstituted
2–8°C· use within 30 days
Somatotropic Axis
GHRH receptor → GH → IGF-1
Research Outcomes
Dosing in Clinical Studies
Protocols from published peer-reviewed trials. Provided for educational reference only — not prescribing guidance.
| Protocol | Dose | Route | Frequency | Indication (Research) |
|---|---|---|---|---|
| FDA-Approved Dosing (EGRIFTA SV) | 2 mg | Subcutaneous injection (abdomen) | Once daily | HIV-associated lipodystrophy (excess abdominal fat) research model |
| Phase 3 Trials (Falutz et al.) | 2 mg/day | Subcutaneous injection | Once daily for 26–52 weeks | Visceral adipose tissue reduction research model |
| Cognitive Research (Baker et al.) | 1 mg/day | Subcutaneous injection | Once daily for 20 weeks | Somatotropic axis / cognitive function research model |
Sources & References
7 sources · research references
Journal of Clinical Endocrinology & Metabolism
Effects of Tesamorelin (TH9507), a GHRH Analog, in HIV-Infected Patients with Excess Abdominal Fat — Pooled Phase 3 Analysis
2010
Falutz J, et al.
Lancet HIV
Tesamorelin for the Reduction of Excess Abdominal Fat in HIV-Infected Patients — LIPO-010 Trial
2019
Stanley TL, et al.
Archives of Neurology
Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults with Mild Cognitive Impairment and Healthy Older Adults
2012
Baker LD, Barsness SM, Borson S, et al.
Journal of Clinical Endocrinology & Metabolism
Effects of Tesamorelin on Muscle Fat and Muscle Area in HIV-Infected Adults
2019
Adrian S, et al.
Obesity Research and Clinical Practice
Body Composition, Hepatic Fat and Metabolic Outcomes of Tesamorelin — Meta-Analysis of Randomized Controlled Trials
2026
Badran AS, et al.
U.S. Food and Drug Administration
EGRIFTA SV (Tesamorelin) Prescribing Information
2025
Theratechnologies Inc.
PubChem Database
Tesamorelin Compound Information
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations. See our Research Use Only policy.
